Top of this page
Skip navigation, go straight to the content

Our Company Magazine Detail

Reinforcing our commitment to rheumatic diseases

  • Posted by

    Rheumatic and musculoskeletal diseases can have a significant impact on quality of life and productivity, while increasing demand for health services. As well as affecting patients directly, these diseases can be a burden on families, employers, insurers and governments.

    In an effort to tackle some of the problems posed by rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis, and systemic lupus erythematosus (SLE), we turn to science for solutions.

    This week thousands of  people with an interest in rheumatic and musculoskeletal diseases will attend the 15th Annual European Congress of Rheumatology (EULAR 2014) in Paris, France.

    EULAR is a major event in the calendar of world rheumatology, and is an important forum for UCB to share the latest data on our existing medicines and potential new therapies currently in development.

    We will have 25 sponsored presentations at EULAR and UCB will also support medical education in SLE through an unrestricted educational grant for a symposium at the Congress.

    In addition, we will host two company-sponsored satellite symposia: one on rheumatoid arthritis and the other on spondyloarthritis.

    As ever, we will have a presence in the exhibition hall at a UCB booth where our representatives will be on hand to answer questions and share the latest clinical and scientific data on our medicines for rheumatic diseases.

    Our strong contribution to this congress demonstrates our ongoing commitment to improving the lives of people with severe diseases by advancing scientific knowledge. At EULAR, delegates will see what it means to be Inspired by Patients. Driven by Science.

    Tags:
    Categories:
    Share:
  • Like

Leave a Comment